Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea | Zendy

Stephanie N. Taylor | Zendy; Jeanne Marrazzo | Zendy; Byron E. Batteiger | Zendy; Edward W. Hook | Zendy; Arlene C. Seña | Zendy; Jill Long | Zendy; Michael R. Wierzbicki | Zendy; Hannah Kwak | Zendy; Shacondra M. Johnson | Zendy; Kenneth Lawrence | Zendy; John P. Mueller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Author(s) -

Stephanie N. Taylor,

Jeanne Marrazzo,

Byron E. Batteiger,

Edward W. Hook,

Arlene C. Seña,

Jill Long,

Michael R. Wierzbicki,

Hannah Kwak,

Shacondra M. Johnson,

Kenneth Lawrence,

John P. Mueller

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1706988

Subject(s) - gonorrhea , neisseria gonorrhoeae , genitourinary system , antibiotics , medicine , microbiology and biotechnology , neisseriaceae , biology , immunology , human immunodeficiency virus (hiv)

Antibiotic-resistant Neisseria gonorrhoeae has prompted the development of new therapies. Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis. In this multicenter, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research